Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 56   

Articles published

GSK 1,473.00 -16.00 (-1.07%)
price chart
US top court rules for Glaxo on overtime pay
By a 5-4 vote, the high court handed a defeat to two former sales representatives for a unit of Britain's GlaxoSmithKline Plc. They had appealed a U.S. appeals court in California ruling that they were "outside sales" personnel exempt from federal ...
Glaxo to Pay at Least $226 Million for Basilea's Toctino
GlaxoSmithKline Plc agreed to buy the marketing rights for Basilea Pharmaceutica AG's hand eczema drug Toctino for 146 million pounds ($226 million).
US approves Glaxo meningitis vaccine for children
The FDA had rejected MenHibrix twice before, in 2010 and 2011, but GlaxoSmithKline said it had resolved regulators' questions about the vaccine's potency and efficacy.
Should investors embrace the profits of sin?
Investors are equally divided on another key component of the Saints: pharmaceuticals companies. GlaxoSmithKline (GSK) and AstraZeneca (AZN) are among the highest-yielding companies in the FTSE 100, yet the rising cost of drug discoveries coupled ...
The Boots takeover could poison one of Britain's best loved firms: We must ...
This ought in theory be a good thing for consumers since the new Boots-Walgreen will have the distribution power to bargain hard with the big drugs firms like GlaxoSmithKline and the beauty-consumer products giants Proctor & Gamble and Unilever.
No Overtime for Drug Reps
Monday's decision came in a case involving GlaxoSmithKline PLC, which was fighting legal claims from two former salesmen who were seeking overtime pay on behalf of a nationwide class of representatives employed by the drug maker.
Higher-risk fund aims for smoother income
Our second Mixed Asset award focuses on higher-risk funds, likely to have a much higher exposure to shares than their lower-risk counterparts.
Social lending: A virtuous circle
Peer-to-peer lending has gained traction with savers and investors in recent years, helped by dire interest rates on offer at banks and building societies, as well as high inflation eroding real returns.
Capital preservation paramount for absolute return funds
For the first time, the Money Observer awards include an accolade for the best Absolute Return fund. These funds, which aim for a positive return every year rather than just trying to outperform a stockmarket index, have become increasingly popular in ...
Jump in hostile takeover bids
GlaxoSmithKline, the pharmaceutical group, recently turned hostile in its $2.6bn bid for US-listed Human Genome Sciences after its initial unsolicited offer was rebuffed.